Can a lifetime guarantee boost value-based care?

Cheryl Bednar, 54, of Laflin, Penn., suffered from chronic pain from hip deterioration until Geisinger Dr. James Murphy performed a hip replacement in February 2018 and offered the lifetime guarantee. (Image from Geisinger)

Swiss orthopedics company Medacta International and Geisinger Health System have said they will pilot a lifetime guarantee program for knee replacement surgeries.

The program will cover full costs for screened Geisinger Health Plan members who receive knee replacement surgery while also ensuring reimbursement for any associated future care the patients may incur throughout their lifetimes. Medacta and Geisinger will share the costs of the implant and associated hospital fees while patients remain on the Geisinger Health Plan and are treated by Geisinger providers.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Can a lifetime guarantee boost value-based care? appeared first on MassDevice.

Medacta IPO on track for Q2

MedactaSwiss medical device maker Medacta Group is reportedly on track for an initial public offering during the second quarter.

The company would issue a limited amount of shares into public trading, maintaining the founding Siccardi family’s control intact, according to Reuters. The IPO would also include an over-allotment option, the newswire reported. Rumors of the transaction first aired last fall.

The orthopedic implant maker, which employs 930 people, posted €273 million ($307 million) in sales last year; adjusted earnings before interest, taxes, depreciation & amortization were 32% of sales.

“We believe the planned IPO will allow us to further increase awareness and visibility of Medacta and facilitate access to international talent,” CEO Francesco Siccardi told the news service.

Credit Suisse and Morgan Stanley joint boo-runners for the deal, with Rothschild as financial adviser.

The post Medacta IPO on track for Q2 appeared first on MassDevice.

Report: Medacta readies for Swiss IPO


Swiss medtech company Medacta is preparing for an initial public offering on the SIX Swiss Exchange for next spring, according to a Reuters report.

The deal is being led by Credit Suisse and Morgan Stanley and joined by JP Morgan and UBS, three people familiar with the matter told Reuters.

Neither the company or the banks indicated in the deal have commented on the matter, according to the report.

Medacta pulls in annual sales of approximately $300 million, and is likely to float a minority stake initially, Reuters reports. The company employs around 930 people and develops orthopedic devices for the knee and spinal market.

Last month, Medacta said that it moved current exec VP Francesco Siccardi to the corner office, taking over the CEO role from founder Dr. Alberto Siccardi, who remained as board president, as of November 1.

The post Report: Medacta readies for Swiss IPO appeared first on MassDevice.

7 medtech stories we missed this week: May 25, 2018

[Image from]

From Mauna Kea receiving FDA clearance to Medacta getting clearance for its pedicle screw placement guide, here are seven medtech stories we missed this week but thought were still worth mentioning.

1. Mauna Kea wins FDA nod for neurosurgery indication

Mauna Kea announced in a May 24 press release that it has received FDA 510(k) clearance for its Celivizio 100 series F400 and F800 with new Confocal Miniprobe, the CranioFlex. The clearance allows the device to be used during neurosurgical procedures. The Cellvizio 100 with CranioFlex gives allows for imaging of tissue internal microstructures and allows for identification of cells and vessels and their organization in the central nervous system during cranial diagnostic and therapeutic procedures. The F400 series operates at 488 nm and the F800 model operates at 800 nm.

2. Bonesupport, Collagen Matrix ink deal

Bonesupport has signed a strategic agreement with Collagen Matrix to expand its product offering to the U.S., according to a May 24 press release. The agreement states that Bonesupport will start selling and marketing some of the Collagen Matrix bone graft substitute products under its own brand and through its own distribution network in the fourth quarter of this year.

3. Implanet launches Jazz Evo spine implant

Implanet announced in a May 23 press release that it has launched its Jazz Evo implant that is designed to respond to the constraints of vertebral fusion indications in adults. The implant is designed to facilitate the treatment of degenerative pathologies in adults and is part of the company’s Jazz range of products that block the braid with a single screw to ensure optimum clamping on the rod without damaging the braid.

4. MC10 wins FDA nod for BioStamp nPoint wireless patient monitor

MC10 recently received FDA 510(k) clearance for its BioStamp nPoint System, according to a May 16 press release. The system is a wireless, biometric data collection platform that is designed to be used by healthcare professionals and researchers for collecting physiological data continuously in the home or in traditional healthcare settings. It is specifically designed for clinical trials or research studies where continuous collective data is needed. It features flexible, body-conforming rechargeable sensor patches that are reusable and can record data for up to 24 hours. It can be configured to measure, record and display general activity, postural classifications, vital signs and sleep metric with clinical validated accuracy.

5. FDA clears second XableCath peripheral catheter

XableCath announced in a May 24 press release that it has received FDA clearance for its XableCath abrasion tip support catheter. This clearance marks the second clearance for the company after its blunt tip catheter was cleared at the end of 2017. Both XableCath’s designs are designed to easily slide past occluding atheroma through the true lumen of the vessel.

6. CrossRoads Extremity Systems launches DynaForce foot implant

CrossRoads Extremity Systems has launched its Active Stabilization MPJ Implant System, according to a May 22 press release. The company launched the product after it received FDA clearance for its DynaForce system. The DynaForce Active Stabilization MPJ Implant System combines stability and an anatomic plate with active compression of a nitinol clip that is delivered to the operating room in a sterile package.

7. FDA clears Medacta pedicle screw guide

Medacta announced in a May 23 press release that it has received FDA clearance for its MySpine Midline Cortical Pedicle Screw Placement Guide. The MySpine MC system allows surgeons to optimize procedures for both outpatient and inpatient settings for a more rapid patient recovery through accurate and reliable muscle-sparing approaches to posterior lumbar surgery. The system guides the screw to a trajectory in the pedicle that has evolved from a cortical bone trajectory. The system also avoids interference with cranial facet joins and can accommodate larger screw diameters and lengths with four points of cortical bone purchase.

The post 7 medtech stories we missed this week: May 25, 2018 appeared first on MassDevice.

9 orthopedic products from AAOS 2018 you need to know

The American Academy of Orthopedic Surgeons’s annual meeting is an opportunity for industry professional to come together and showcase some of their latest orthopedic solutions, research and technology. The meeting is being held in New Orleans at the Morial Convention Center, March 6-10.

This year, a number of orthopedic companies have launched some of their latest technology in hip replacement, knee replacement and more.

From Stryker launching its knee implant for Mako robotic system to Medacta releasing its Moto medial partial knee, shoulder system and hip system, here are 9 orthopedic products from the American Academy of Orthopedic Surgeons annual meeting.

Next >>

The post 9 orthopedic products from AAOS 2018 you need to know appeared first on MassDevice.

Medacta wins FDA nod for 3DMetal knee revision implants



Medacta said today it won FDA clearance for its 3DMetal tibial cones designed for knee revision surgery.

The first procedures with the device were recently performed by Dr. Kevin Hardt and device designer Dr. David Manning of Chicago’s Northwestern University Feinberg School of Medicine and Dr. Dragan Jeremic of Brakel, Germany’s St. Vincenz Krankenhaus, the Switzerland-based compay said..

“Medacta’s 3DMetal Tibial Cones recreate a proximal structural foundation for the intended revision implant by achieving proximal fixation and force transmission in the remaining host bone,” Dr. Manning said in a prepared statement.

“The instrumentation was straightforward to use and complementary to my typical revision workflow. I was impressed with the surgical press fit of the implant,” Dr. Hardt said in a press release.

“I am very satisfied with this new implant and the result. From now on, this will be an excellent option for my patients,” Dr. Jeremic said in prepared remarks.

The newly cleared 3DMetal tibial cones are designed to be used as structural support in areas of bone deficiencies which could compromise revision implant fixation and are cleared for use with the company’s GMK revision and GMK hinge knee systems and GMK tibial extension stems and offsets.

“It is Medacta’s mission to be a partner for our surgeons, even in the most challenging scenarios. With our innovative 3DMetal technology, we have extended the range of advanced solutions for our surgeons and we will continue to do so in the future,” Medacta EVP Francesco Siccardi said in a press release.

Last month, Medacta said it won FDA clearance for its Anatomic shoulder and reverse shoulder components designed as part of its Medacta shoulder system.

Medacta wins FDA nod for anatomic, reverse shoulder repair components



Medacta said today it won FDA clearance for its Anatomic shoulder and reverse shoulder components designed as part of its Medacta shoulder system.

The Chicago-based company touted that the 1st successful procedure using the device was recently performed at Northwestern Memorial Hospital by Dr. Matthew Saltzman.

“The procedure went very well. The Medacta Shoulder System’s instrumentation and implants allow for impressive anatomic restoration, resulting in an efficient surgery and, hopefully, improved patient outcomes,” Dr. Saltzman said in a press release.

The Medacta shoulder system was released in February this year and is a modular platform which features a wide range of sizes and options for a range of compatibility with different anatomies, the company said.

“The new Medacta Shoulder System is a continuation of our effort to improve orthopedic implant design and configurability for the benefit of both surgeons and their patients. This latest surgery in the United States marks a milestone for Medacta in line with our company’s patient-centric vision and the same ambition that has helped us become a leader in knee, hip, and spine technology,” Medacta exec VP Francesco Siccardi said in a prepared statement.